Expert oncologists discuss the evolving treatment paradigm of TROP2-directed antibody drug conjugates in patients with metastatic non-small cell lung cancer.
EP. 1: Coming Soon: Evolving Strategies for Treating Metastatic Non-Small Cell Lung Cancer: Focus on TROP2-Directed ADCs
Expert oncologist Anne Tsao, MD, shares her excitement for an upcoming precision medicine program focused on the evolving role of TROP2-directed antibody drug conjugates in metastatic non-small cell lung cancer.
2 Clarke Drive Cranbury, NJ 08512